Alnylam Pharmaceuticals, Inc.
RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

Abstract:

The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.